Kenneth Boyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12023958/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors. Current Pediatrics Reports, 2022, 10, 109-124.	4.0	1
2	Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Scientific Reports, 2017, 7, 11496.	3.3	97
3	Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Neglected Tropical Diseases, 2017, 11, e0005670.	3.0	34
4	Reply to Wallon and Peyron. Clinical Infectious Diseases, 2016, 62, 812-814.	5.8	4
5	<i>ALOX12</i> in Human Toxoplasmosis. Infection and Immunity, 2014, 82, 2670-2679.	2.2	28
6	Management of Congenital Toxoplasmosis. Current Pediatrics Reports, 2014, 2, 166-194.	4.0	46
7	Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult. Journal of Neuroparasitology, 2012, 3, 1-8.	0.6	13
8	ldentification of a Sporozoite-Specific Antigen from Toxoplasma gondii. Journal of Parasitology, 2011, 97, 328-337.	0.7	151
9	Unrecognized Ingestion of Toxoplasma gondii Oocysts Leads to Congenital Toxoplasmosis and Causes Epidemics in North America. Clinical Infectious Diseases, 2011, 53, 1081-1089.	5.8	158
10	Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Scientia Medica, 2010, 20, 20.	0.3	14
11	Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Scientia Medica, 2010, 20, 20-26.	0.3	10
12	Longitudinal Study of New Eye Lesions in Children with Toxoplasmosis Who Were Not Treated During the First Year of Life. American Journal of Ophthalmology, 2008, 146, 375-384.e4.	3.3	106
13	Toxoplasmosis-Associated Neovascular Lesions Treated Successfully With Ranibizumab and Antiparasitic Therapy. JAMA Ophthalmology, 2008, 126, 1152.	2.4	52
14	Genetic and Epigenetic Factors at COL2A1 and ABCA4 Influence Clinical Outcome in Congenital Toxoplasmosis. PLoS ONE, 2008, 3, e2285.	2.5	102
15	Cataracts in congenital toxoplasmosis. Journal of AAPOS, 2007, 11, 551-554.	0.3	34
16	SEVERE SULFADIAZINE HYPERSENSITIVITY IN A CHILD WITH REACTIVATED CONGENITAL TOXOPLASMIC CHORIORETINITIS. Pediatric Infectious Disease Journal, 2006, 25, 270-272.	2.0	51
17	Impact of Visual Impairment on Measures of Cognitive Function for Children With Congenital Toxoplasmosis: Implications for Compensatory Intervention Strategies. Pediatrics, 2006, 118, e379-e390.	2.1	50
18	Outcome of Treatment for Congenital Toxoplasmosis, 1981-2004: The National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clinical Infectious Diseases, 2006, 42, 1383-1394.	5.8	322

#	Article	IF	CITATIONS
19	Absence of Sensorineural Hearing Loss in Treated Infants and Children with Congenital Toxoplasmosis. Otolaryngology - Head and Neck Surgery, 1992, 106, 75-80.	1.9	57